Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat + dapagliflozin vs placebo + dapagliflozin in chronic kidney disease with hypertension (BaxDuo-Pacific, Japan)
jRCT2041240181Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of baxdrostat in chronic kidney disease (CKD), hypertension (HTN) and cardiac morbidity (3 arms), sponsored by AstraZeneca. Primary endpoints: Composite of sustained ≥50% decline in eGFR, Composite endpoint of kidney failure and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
baxdrostat
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on jRCT2041240181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240181.